JP2016502526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502526A5 JP2016502526A5 JP2015542769A JP2015542769A JP2016502526A5 JP 2016502526 A5 JP2016502526 A5 JP 2016502526A5 JP 2015542769 A JP2015542769 A JP 2015542769A JP 2015542769 A JP2015542769 A JP 2015542769A JP 2016502526 A5 JP2016502526 A5 JP 2016502526A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- binding antibody
- composition according
- subject
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727334P | 2012-11-16 | 2012-11-16 | |
| US61/727,334 | 2012-11-16 | ||
| PCT/US2013/070042 WO2014078502A1 (en) | 2012-11-16 | 2013-11-14 | Use of il-1 beta binding antibodies for treating peripheral arterial disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016502526A JP2016502526A (ja) | 2016-01-28 |
| JP2016502526A5 true JP2016502526A5 (enExample) | 2016-12-28 |
Family
ID=49679654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542769A Pending JP2016502526A (ja) | 2012-11-16 | 2013-11-14 | 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10000565B2 (enExample) |
| EP (1) | EP2919811B1 (enExample) |
| JP (1) | JP2016502526A (enExample) |
| AU (1) | AU2013344796B2 (enExample) |
| CA (1) | CA2891556A1 (enExample) |
| WO (1) | WO2014078502A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3303388A1 (en) | 2015-06-04 | 2018-04-11 | Novartis AG | Use of il-1 beta binding antibodies to treat peripheral arterial disease |
| US20180291097A1 (en) * | 2015-06-04 | 2018-10-11 | Craig Basson | Use of il-1 beta binding antibodies to treat peripheral arterial disease |
| AU2016302539A1 (en) | 2015-07-31 | 2018-02-08 | Glaxosmithkline Intellectual Property Development Limited | Antibody variants |
| EP3380611A4 (en) * | 2015-11-24 | 2020-02-12 | Commonwealth Scientific and Industrial Research Organisation | PRODUCTION OF VIRUSES IN A CELL CULTURE |
| EP3487584A1 (en) * | 2016-07-21 | 2019-05-29 | Novartis AG | Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis |
| EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3046093A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
| RU2020113234A (ru) * | 2017-09-13 | 2021-10-13 | Новартис Аг | ПРИМЕНЕНИЕ АНТИТЕЛ, СВЯЗЫВАЮЩИХ IL-1β, ДЛЯ ЛЕЧЕНИЯ АЛКОГОЛЬНОГО ГЕПАТИТА |
| KR102880762B1 (ko) * | 2018-09-20 | 2025-11-03 | 에스에프제이 파마 엑스, 인코포레이티드 | 티카그렐러 활성을 반전시키는 방법 |
| JP7482866B2 (ja) | 2018-11-19 | 2024-05-14 | ビオラ・セラピューティクス・インコーポレイテッド | 生物学的治療薬による疾患処置方法およびデバイス |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN112402359A (zh) * | 2020-11-04 | 2021-02-26 | 深圳前海鹰岗生物科技有限公司 | 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法 |
| WO2026003765A1 (en) | 2024-06-25 | 2026-01-02 | Kiniksa Pharmaceuticals, Gmbh | Formulations of anti-interleukin 1 receptor 1 antibodies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| WO2008077145A2 (en) | 2006-12-20 | 2008-06-26 | Xoma Technology Ltd. | Treatment of il-1-beta related diseases |
| US20110110920A1 (en) | 2008-03-26 | 2011-05-12 | Orthologic Corp. | Method of treating peripheral arterial disease |
| SG191625A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AU2009256250B2 (en) | 2008-06-03 | 2013-05-30 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| AU2009289545A1 (en) * | 2008-09-05 | 2010-03-11 | Xoma (Us) Llc | Methods for improvement of beta cell function |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| EP2391652A4 (en) | 2009-01-29 | 2013-01-02 | Abbott Lab | IL-1 BINDING PROTEINS |
| SG176265A1 (en) * | 2009-05-29 | 2012-01-30 | Xoma Technology Ltd | CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF |
| BR112012007365A2 (pt) | 2009-10-15 | 2016-11-22 | Abbott Lab | proteínas de ligação à il-1 |
| MX341579B (es) * | 2010-08-03 | 2016-08-25 | Abbvie Inc * | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| WO2013049278A1 (en) * | 2011-09-30 | 2013-04-04 | Novartis Ag | USE OF IL-1 ß BINDING ANTIBODIES |
-
2013
- 2013-11-14 WO PCT/US2013/070042 patent/WO2014078502A1/en not_active Ceased
- 2013-11-14 EP EP13798486.0A patent/EP2919811B1/en not_active Not-in-force
- 2013-11-14 CA CA2891556A patent/CA2891556A1/en not_active Abandoned
- 2013-11-14 JP JP2015542769A patent/JP2016502526A/ja active Pending
- 2013-11-14 AU AU2013344796A patent/AU2013344796B2/en not_active Ceased
- 2013-11-14 US US14/442,536 patent/US10000565B2/en active Active
-
2018
- 2018-05-21 US US15/984,993 patent/US20180258166A1/en not_active Abandoned
-
2019
- 2019-06-21 US US16/448,341 patent/US20200148759A1/en not_active Abandoned
-
2021
- 2021-04-15 US US17/231,400 patent/US20210317202A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016502526A5 (enExample) | ||
| Wiegand et al. | Treatment of lymphatic malformations with the mTOR inhibitor sirolimus: a systematic review | |
| KR102446673B1 (ko) | 암 치료를 위한 약물의 제조에 있어서 항-pd-1 항체 및 vegfr 억제제의 조합의 용도 | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP5417653B2 (ja) | 抗−４−１ｂｂ抗体及び化学抗癌剤を含む癌疾患の予防及び治療用調合薬学的組成物 | |
| JP2015187125A5 (enExample) | ||
| JP2015530867A5 (enExample) | ||
| JP2017528427A5 (enExample) | ||
| JP2017537105A5 (enExample) | ||
| KR20180018695A (ko) | 항암제 | |
| RU2471483C2 (ru) | Противоопухолевые комбинации, содержащие ингибитор vegf и иринотекан | |
| JP2023071715A (ja) | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 | |
| JP2013506684A5 (enExample) | ||
| JP2016537380A5 (enExample) | ||
| KR20240090993A (ko) | 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체 | |
| RU2011150619A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения | |
| Frappaz et al. | Phase 1 study of dalotuzumab monotherapy and ridaforolimus–dalotuzumab combination therapy in paediatric patients with advanced solid tumours | |
| Deronic et al. | The quinoline-3-carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment during sterile inflammation: leukocyte-and context-specific effects | |
| RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
| JP2019533715A5 (enExample) | ||
| RU2018114457A (ru) | Лечение syd985 пациентов с t-dm1 рефрактерным раком | |
| RU2020133811A (ru) | Фармацевтические комбинации | |
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| US20240173403A1 (en) | Combination of AXL Antibodies and ACE Inhibitors in the Treatment of Fibrosis | |
| AU2019392742A1 (en) | Anti-cancer activity of adamantane derivatives |